Combinostics’ solution supports healthcare professionals in the diagnosis and treatment of neurodegenerative diseases.
There are still no effective treatments for neurodegenerative diseases like Alzheimer’s, but early-stage diagnosis, combined with symptomatic treatment and lifestyle intervention, can make a drastic difference to the quality of life in later years. A vast amount of heterogeneous data is collected during the diagnostic workup, so it can be challenging for healthcare professionals to interpret and identify relationships that exist between different data sets.
Combinostics has developed a state-of-the-art machine vision solution for early detection of Alzheimer’s, by analyzing the MRI scan of your brain and your clinical data against a global anonymized database. Their self-learning approach makes every subsequent scan more accurate than the previous.
The overall goal is to improve patient quality of life in later years and is already used by radiology and neurology departments from around the world in the EU, US, Japan, and South Korea.
P.S. Already in 2015, our Investment Director Claes Mikko helped Combinostics to raise their first investment round when managing the national Finnish angel network. The cooperation is continuing strong! 🤝